Finance

Beta
Lists
STX:LON
Shield Therapeutics PLC
GBX 5.75
-1.71%
(-0.100) 1D
Jun 3, 5:07:48 PM GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for STX...
Open
GBX 5.89
High
GBX 6.00
Low
GBX 5.70
Mkt. cap
61.43M
Avg. vol.
2.65M
Volume
1.83M
52-wk high
GBX 12.50
52-wk low
GBX 2.30
EPS
-GBX 0.01
Shares outstanding
1.07B
No. of employees
68
Open
GBX 5.89
High
GBX 6.00
Low
GBX 5.70
Mkt. cap
61.43M
Avg. vol.
2.65M
Volume
1.83M
52-wk high
GBX 12.50
52-wk low
GBX 2.30
EPS
-GBX 0.01
Shares outstanding
1.07B
No. of employees
68
News stories
From sources across the web
About Shield Therapeutics PLC
CEOGreg Madison
Employees68
Founded2008
Headquarters-
SectorPharmaceutical industry
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
10.72M
10.72M
14.13M
14.13M
Cost of goods sold
5.43M
5.43M
7.90M
7.90M
Cost of revenue
5.43M
5.43M
7.90M
7.90M
Research and development expenses
370.50K
370.50K
399.00K
399.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.82M
7.82M
7.97M
7.97M
Operating expense
8.19M
8.19M
8.36M
8.36M
Total operating expenses
13.62M
13.62M
16.26M
16.26M
Operating income
-2.90M
-2.90M
-2.13M
-2.13M
Other non operating income
-
-
-
-
EBT including unusual items
-4.69M
-4.69M
-3.88M
-3.88M
EBT excluding unusual items
-4.69M
-4.69M
-3.88M
-3.88M
Income tax expense
79.00K
79.00K
178.00K
178.00K
Effective tax rate
-1.68%
-1.68%
-4.59%
-4.59%
Other operating expenses
-
-
-18.00K
-18.00K
Net income
-4.77M
-4.77M
-4.06M
-4.06M
Net profit margin
-44.46%
-44.46%
-28.74%
-28.74%
Earnings per share
-
-
-
-
Interest and investment income
84.50K
84.50K
79.00K
79.00K
Interest expense
-1.88M
-1.88M
-1.83M
-1.83M
Net interest expenses
-1.79M
-1.79M
-1.75M
-1.75M
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.73M
-2.73M
-1.74M
-1.74M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more